NPS is a non-thermal drug-free tissue treatment technology that can stimulate unique behaviors in cells by applying ultra-short nanosecond duration electrical pulses that affect the cell membrane and intracellular structures. NPS can be used for tissue removal by inducing cell death in tissue cells with minimal inflammatory response, which improves healing and supports the replacement of treated tissue cells with healthy tissue cells. In preclinical cancer studies, NPS has been shown to induce immunogenic cell death, a cell death process that destroys the treated cells and exposes the tumor cell antigens to the immune system, resulting in the generation of cytotoxic T-cells and the mounting of an adaptive immune response targeted against the tumor cells.
PulseTx is the Company’s proprietary NPS delivery platform designed for broad application across many tissue treatment indications. The PulseTx system features a tunable nanosecond pulse generator capable of generating pulses of varying pulse duration, amplitude, frequency and number. It is designed to be used with a suite of interchangeable tissue applicators that are customized to the tissue being treated.
“The PulseTx 510(k) submission is an important step in our mission to
improve healthcare by delivering this unique technology to physicians
and their patients,” said
All statements in this press release that are not historical are
forward-looking statements, including, among other things, statements
relating to Pulse Biosciences’ expectations regarding regulatory
clearance, the mechanism of action of NPS treatments, planned future
clinical trials, and other matters related to its pipeline of product
candidates and other future events. These statements are not historical
facts but rather are based on Pulse Biosciences’ current expectations,
estimates, and projections regarding Pulse Biosciences’ business,
operations and other similar or related factors. Words such as “may,”
“will,” “could,” “would,” “should,” “anticipate,” “predict,”
“potential,” “continue,” “expects,” “intends,” “plans,” “projects,”
“believes,” “estimates,” and other similar or related expressions are
used to identify these forward-looking statements, although not all
forward-looking statements contain these words. You should not place
undue reliance on forward-looking statements because they involve known
and unknown risks, uncertainties, and assumptions that are difficult or
impossible to predict and, in some cases, beyond Pulse Biosciences’
control. Actual results may differ materially from those in the
forward-looking statements as a result of a number of factors, including
those described in Pulse Biosciences’ filings with the
View source version on businesswire.com: http://www.businesswire.com/news/home/20170314005585/en/
Pulse Biosciences, Inc.
President and Chief Executive Officer
Sam Brown, Inc.
Hannah Hurdle, 805-601-5331